Cancer Immunotherapy Utilizing A Novel Receptor For Programmed Cell Death-1 Ligand 2
Funder
National Health and Medical Research Council
Funding Amount
$577,857.00
Summary
Immuno-modulators utilize the patient’s own immune system to eliminate or slow the growth of cancerous cells. We have identified a novel immuno-modulator which could be a significant player in immune-modulation therapy for the treatment of cancer. We will use the development grant to develop a product which has significant potential to be the next generation treatment for cancer.
Organ transplantation is the measure of last resort for patients with organ failure. While this is a life-saving procedure, the long-term survival of transplant recipients depends on maintaining the new organ without rejecting it. The proposed research will create novel test systems that allow both patients and clinicians to monitor the concentration of the drugs required to suppress organ rejection. Such a test will reduce the cost of treatment and increase the long term survival of patients.
A Bispecific Antibody To Synergise Checkpoint Blockers In Oncology
Funder
National Health and Medical Research Council
Funding Amount
$636,492.00
Summary
Cancer hides from the immune system in its earliest stages by evading immune surveillance and a cell type named myeloid derived suppressor cell (MDSC) has been identified as the main accomplice in this evasion. Currently, there is no drugs able to specifically target those cells. Here, we will develop a new drug that will prevent their recruitment to the tumors. We believe that when use in synergy with recent immunotherapies, it will dramatically improve survival in cancer patients.
Development Of A High Acuity, Diamond Retinal Prosthesis
Funder
National Health and Medical Research Council
Funding Amount
$1,010,214.00
Summary
Over recent years our team has developed a retinal implant to restore sight to people with certain types of blindness. With 256 independently controllable electrodes this device is among the most sophisticated in the world. We aim to conduct experiments to demonstrate that our device can provide improved better visual acuity than the world leaders with a view to developing a competitive commercial medical technology.
Compound Culture Media To Improve Human IVF Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$254,340.00
Summary
In Australia 1 in 6 couples require IVF to conceive. Although pregnancy rates have improved over the last 10 years the live birth rate in Australia per cycle is only 17%. This project will assess a new method for the culture of embryos for the ability to maintain embryo vitality and produce healthy babies.
Development Of A Novel Microfluidic Device To Treat Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$508,397.00
Summary
This research aims to develop a novel technology for the separation of high quality sperm. It is envisaged this will replace existing technology to improve the reproductive outcomes of both humans, as well as animals.
From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.
Development And Validation Of A Latent Tuberculosis Diagnostic
Funder
National Health and Medical Research Council
Funding Amount
$534,865.00
Summary
Globally, tuberculosis is a leading cause of death with 9.6 million new diagnoses in 2014. The diagnosis of latent TB infection is important, but is difficult to make because current assays are suboptimal. We have developed a very simple assay which detects responses to TB antigens by co-expression of two surface markers expressed by CD4+ T cells. We propose to develop this into a highly standardised kit for the diagnosis of TB with our commercial partner Cytognos.
Preclinical Development Of Q2361, A Transforming New Drug For Skin Cancer Prevention In Organ Transplant Recipients
Funder
National Health and Medical Research Council
Funding Amount
$724,957.00
Summary
Patients that receive organ transplants need additional medications in order to prevent organ rejection. Unfortunately, these drugs carry an unwanted side-effect - they permit the development of skin cancer. Currently, other than surgery, little can be done to help these patients. Our preliminary data suggest that a new drug may prevent these skin cancers from forming. This project aims to deliver key insights into the influence of this drug and its role in skin cancer prevention.